Oral cavity adjuvant therapy (OCAT) -a phase III, randomized controlled trial of surgery followed by conventional RT (5 fr/wk) versus concurrent CT-RT versus accelerated RT (6fr/wk) in locally advanced, resectable, squamous cell carcinoma of oral cavity

Sarbani Ghosh Laskar(Tata Memorial Hospital), D'Cruz Anil(Apollo Hospitals), Anuj Kumar(Tata Memorial Hospital), Anuja Deshmukh(Tata Memorial Hospital), Tejpal Gupta(Tata Memorial Hospital), Vijay Patil(Homi Bhabha National Institute), Mandar Deshpande(Tata Memorial Hospital), Jai Prakash Agarwal(Tata Memorial Hospital), Monali Swain(Tata Memorial Hospital), Deepa Nair(Homi Bhabha National Institute), Shwetabh Sinha(Homi Bhabha National Institute), Vedang Murthy(Homi Bhabha National Institute), Vanita Noronha(Homi Bhabha National Institute), Amit Joshi(Dr. Rajendra Prasad Government Medical College), Gouri Pantvaidya(Tata Memorial Hospital), Sudhir Nair(Homi Bhabha National Institute), Pankaj Chaturvedi(Homi Bhabha National Institute), Santam Chakraborty(Tata Medical Center), Kumar Prabhash(Homi Bhabha National Institute), Ashwini Budrukkar(Tata Memorial Hospital), Abhishek Chatterjee(Homi Bhabha National Institute), Devendra Chaukar, Prathamesh Pai(Tata Memorial Hospital)
European Journal of Cancer
December 26, 2022
Cited by 29


Related Papers